Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
CIRM presents strategic reprioritization, DEI measures and patient-assistance pilot
Summary
CIRM President Jonathan Thomas told the CFAOC that the agency is repositioning its Prop 14 funds toward basic research, tools, rare-disease BLA-stage projects and access programs; he described DEI scoring for grants, a $15.6 million seed for a patient-assistance fund (now >$16M), and plans for community care centers and education initiatives.
Jonathan Thomas, president and CEO of the California Institute for Regenerative Medicine (CIRM), presented a strategic-plan update to the Citizens Financial Accountability Oversight Committee on Dec. 18, 2024, outlining a reprioritization of remaining Prop 14 funds and new program pilots aimed at improving access, equity and workforce development.
Thomas summarized CIRM's evolution from the original Prop 71 funding to Prop 14, noting that the agency now manages roughly $8.5 billion in voter-authorized funding. He described a multi-pillar allocation framework that emphasizes discovery/basic research, tools and technologies (for example, gene editing), rare-disease projects targeted for biologics license application…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
